There is evidence that the share of rapid debrisoquine metabolizers is higher in BEN patients than in healthy controls [13], thus polymorphic variants in CYP2D6 causing sensitivity to various chemical agents are suspected in BEN pathogenesis. The gene discussed is CYP2D6; the disease is Balkan nephropathy.